



PACIFIC THERAPEUTICS LTD. ANNOUNCES NEW CFO

VANCOUVER, BRITISH COLUMBIA- April 27, 2016 - Pacific Therapeutics Ltd. (CSE:PT) (OTC:PCFTF) (FSE: 1P3) ("Pacific" or the "Company") is pleased to announce the appointment of Mr. Abbey Abdiye as Chief Financial Officer (CFO) following Mr. Derick Sinclair's resignation as CFO.

Mr. Abdiye is an experienced finance professional, holding a CPA designation. He has years of experience with both private and public companies. He is currently CFO of BioMark Diagnostics Inc. (CSE: BUX), a leading cancer diagnostic company in Phase III trials.

With respect to Mr. Abdiye's appointment, Robert Horsley, the Company's CEO stated: "We are pleased to bring someone with Abbey's background and track record of success to Pacific Therapeutics. We also would like to thank Mr. Derick Sinclair, the outgoing CFO, for his work and efforts. We wish him the best in his future endeavors. He will remain on the Board of Directors."

About Pacific Therapeutics Ltd.

Pacific Therapeutics Ltd. is an early stage Vancouver-based pharmaceutical company focused on developing an herbal supplement, BP120, which is aimed at the treatment of immune deficiency and hypertension.

For further information, please contact: Robert Horsley, Director & CEO
rnpshorsley@gmail.com
(604) 559-8051

The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.

FORWARD LOOKING STATEMENTS

Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Readers should not place undue reliance on the Company's forward-looking statements, as the Company's actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company's business, or if the Company's estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize. Factors that could cause actual results to differ materially from those in forward looking statements include, the timing and receipt of government and regulatory approvals, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process, and continued availability of capital and financing and general economic, market or business conditions, and fees charged by service providers. The forward-looking statements included in this news release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.